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Setting of Extensive Bone
Marrow Involvement
Although a graft-versus-malignancy effect is well
documented in many hematologic malignancies [1],
the issue of whether a graft-versus-Hodgkin lymphoma
(HL) effect does exist has been the subject of consider-
able controversy [2]. Responses to donor leukocyte in-
fusions (DLIs) are often viewed as the gold standard
to establish a graft-versus-HL effect. DLI response
rates (complete plus partial responses) reported in the
literature in patients not receiving concomitant salvage
chemotherapy are in the 30%-40% range [3,4].
Achievement of a complete response after DLIs is asso-
ciated with the development of acute or chronic GVHD
(aGVHD, cGVHD) [3]. In these cases, objective docu-
mentation of disease progression by biopsy or disease
regression by imaging or other diagnostic studies is
not usually provided. Moreover, it is not clear whether
responses can be achieved even in patients with dissem-
inated, high-volume disease (eg, extensive marrow in-
volvement), or primarily in patients with localized,
low-volume tumor burden.A 26-year-old man was diagnosed with stage IIB
‘‘bulky’’ HL in November 2003. He failed to respond
to ABVD (doxorubicin, bleomycin, vinblastine, dacar-
bazine), and achieved a partial response to ESHAP
(etoposide, methylprednisolone, cytarabine, cisplatin).
In October 2004, he underwent BEAM (carmustine,
etoposide, cytarabine, melphalan) high-dose chemo-
therapy and autologous peripheral blood stem cell
transplantation (PBSCT). In January 2005, restaging
revealed disease progression and he received salvage
chemotherapy with COPP (cyclophosphamide, pred-
nisone, procarbazine, vincristine) for 3 cycles, leading
to a partial response.
On May 5, 2005, the patient underwent an unma-
nipulated matched unrelated donor marrow transplant.
His conditioning regimen included fludarabine, mel-
phalan, and thymoglobulin. He was treated as part of
an institutional review board (IRB)-approved protocol,
and he provided written informed consent.
He achieved 100% donor-derived engraftment by
peripheral blood chimerism studies and an initial com-
plete remission with his day 30 restaging (July 2005).
Around that time he also developed limited, biopsy-
proved, steroid-responsive cutaneous GVHD. He
subsequently reported low back pain, and in Novem-
ber 2005, a 2-deoxy-2-[18F]fluoro-D-glucose (FDG)
positron emission tomography/computed tomogra-
phy (PET-CT) study showed a hypermetabolic hypo-
dense lesion in the marrow of the right sacral ala. A
pelvic magnetic resonance imaging study in February
2006 showed an infiltrative process involving the rightFigure 1. (A, left) This displays the May 11, 2007, positron-emission tomography (PET)-computed tomography (CT) scan showing recurrent
disease with multiple, extensive PET-positive lesions throughout the skeleton, and retroperitoneal adenopathy. (B, right) This shows the August
1, 2007, PET-CT study showing complete resolution of the multifocal osseous as well as nodal lesions. PET scans were acquired following the
intravenous injection of 16.9 mCi of 2-deoxy-2-[18F]fluoro-D-glucose (FDG), and noncontrast enhanced CT scans were acquired for attenu-
ation, correction and, diagnosis.
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Letters to the Editor 479Figure 2. Bone marrow biopsy (A) showing Hodgkin cells (center) in a background of small lymphocytes, histiocytes, and marrow fibrosis.
Original hematoxylin & eosin (H&E), 500 magnification. Skin biopsy (B) showing necrotic keratinocytes (arrows) indicating cutaneous
GVHD (original H&E stain,400 magnification). Transjugular liver biopsy (C and D) showing bile-duct damage with necrotic cholangiocytes
(arrows) consistent with hepatic graft-versus-host disease (original H&E stain, 400 magnification).sacrum and the posterior right ilium, as well as proba-
ble involvement of L3 and L5. A biopsy of the right
sacral-based mass in February 2006 revealed recurrent
HL, establishing a reliable correlation between FDG
PET imaging and histologic findings.
The patient received 2 courses of pentostatin, fol-
lowed by a first DLI on May 4, 2006. The CD31 cell
dose infused was 5 106 CD31 cells/kg. This was fol-
lowed by mild, steroid-responsive skin GVHD but no
disease response. An FDG PET-CT scan in mid-June
2006 documented marrow involvement with multiple
hypermetabolic osseous lesions involving ribs, tho-
racic and lumbar spine, bilateral iliac bones, and sa-
crum.
Shortly thereafter, the patient was treated with 2
cycles of hyperfractionated cyclophosphamide, followed
by a second DLI with 2 107 CD31 cells/kg (August
31, 2006). He then developed abdominal pain and profuse
watery diarrhea, and was found to have biopsy-proved
gastrointestinal GVHD. He required high-dose methyl-prednisolone (MP), tacrolimus, infliximab, budesonide,
and pentostatin for GVHD treatment. Restaging in
October 2006 revealed a complete response, with resolu-
tion of his multiple PET-positive marrow-based lesions.
In mid-May 2007 he again was diagnosed with
recurrent disease with multiple FDG PET-positive
osseous lesions throughout the skeleton and retroper-
itoneal adenopathy. Maximal standardized uptake
values (SUVs) varied with the location of the skeletal
lesions, ranging from 5.7 to 12.6 (Figure 1A). A bone
marrow biopsy confirmed marrow involvement with
HL (Figure 2A). Although the patient was being
considered for investigational salvage agents, he devel-
oped a skin rash and jaundice (serum total bilirubin
peaking at 13.3 mg/dL). A skin biopsy (June 20)
showed GVHD (Figure 2B), and a transjugular liver
biopsy (June 22) showed bile-duct damage consistent
with GVHD and no evidence of lymphoma infiltration
(Figure 2C and D). The patient was started on MP
(200 mg intravenously daily), tacrolimus, and
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T cell non-Hodgkin lymphomas (TNHL) are an
uncommon and heterogeneous group of lymphoid
malignancies characterized by a poor prognosis.
They usually present with advanced-stage disease
and high International Prognostic Index (IPI) score
[1]. Patients with TNHL treated with conven-
tional-dose chemotherapy alone in general have
480 Letters to the Editorextracorporeal photopheresis. His jaundice and his
skin rash resolved, and an MP taper was started. Three
weeks later (July 24, 2007) his MP dose was down to 32
mg/day. On August 1, 2007, a follow-up FDG PET-
CT scan on that day showed dramatic and complete
resolution of the tracer uptake in the multifocal mar-
row-based lesions as well as resolution of his retroper-
itoneal adenopathy. The lytic lesions in the marrow
demonstrated interval calcification in keeping with re-
sponse to treatment (Figure 1B). At that time, he was
receiving low-dose MP (8 mg/day), tacrolimus (1 mg
every other day), and weekly extracorporeal photophe-
resis. A follow-up bone marrow biopsy (August 17,
2007) showed a hypocellular marrow and no evidence
of HL infiltration. At that time the patient’s MP dose
had been further reduced to 4 mg/day. At his latest
follow-up (October 2, 2007), his HL remains in clini-
cal remission. His MP dose remains 4 mg/day, and his
tacrolimus dose is 0.5 mg every other day.
We believe this case provides vivid, objective doc-
umentation that a powerful graft-versus-HL effect ex-
ists even in patients with disseminated and extensive
disease (including marrow involvement), albeit over-
lapping in this case with severe skin and hepatic
GVHD. Although it cannot entirely be ruled out
that steroid therapy started for GVHD may have con-
tributed to the most recent response, this patient was
known to have advanced, highly refractory disease.
Such a rapid and generalized response to single-agent
methylprednisolone is unlikely. In addition, his meth-
ylprednisolone dose was quite low at the time of his
FDG PET-CT restaging and repeat marrow biopsy,
and his overall clinical course supports the presence
of a graft-versus-HL effect. The immunologic mecha-
nisms underlying this effect are not clear. Whether and
how this effect can be harnessed and modulated in
a more selective and clinically useful fashion deserves
further study.
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